304am永利集团

Dr. Jun Zhu, aged 45, has joined the Group since December 2020, and currently serves as the Executive Director and Chief Executive Officer of the Company and holds directorship and other positions in certain subsidiaries of the Company and holds directorship and other positions in certain subsidiaries of the Company. Before joining the Group, Dr. Zhu served as the internal medicine physician in Huashan Hospital affiliated to Fudan University in Shanghai, the project manager and global vice-president of IQVIA Holdings Inc., the general manager in Greater China of Omnicare Clinical Research Inc., the founder and chief executive officer of Shanghai PPC Biopharmaceutical Technology Co., Ltd.* (上海百利佳生醫藥科技有限公司). Dr. Zhu obtained a bachelor’s degree in clinical medicine from Fudan University (復旦大學) in China in July 2001, an EMBA degree from Cheung Kong Graduate School of Business (長江商學院) in China in September 2018 and a doctoral degree in health management from University of Montpellier in June 2024.

Mr. Qiyu Chen (陳啟宇), aged 50, has been a non-executive director of the Company since January 2013 and served as the chairman of the Board from December 2018 to November 2021. Mr. Chen joined Fosun Pharma Group in April 1994, and served as a director of Fosun Pharma since May 2005, and served as the chairman of the board of Fosun Pharma from June 2010 to October 2020. Mr. Chen currently serves as the chairman of the board of Fosun High Tech, the executive director and the co-chief executive officer of Fosun International, the non-executive director of Gland Pharma, the non-executive director and vice chairman of the board of Sinopharm, the director of Beijing Sanyuan Foods Co., Ltd.* (北京三元食品股份有限公司) (Shanghai Stock Exchange stock code: 600429), the co- chairman of the board of Unicorn II Holdings Limited. Mr. Chen previously served as a director of Di’an Diagnostics Group Co., Ltd. (迪 安診斷技術集團股份有限公司) (Shenzhen Stock Exchange stock code: 300244), a non-executive director of Babytree Group (Stock Exchange stock code: 01761), and a co-chairman of the board of New Frontier Health Corporation (delisted from the New York Stock Exchange in January 2022 and merged by Unicorn II Holdings Limited by way of merger by absorption). In addition, Mr. Chen previously held directorships in various companies invested by Fosun International and its affiliated companies. 

Mr. Chen has been the chairman of China Medical Pharmaceutical Material Association (中國醫藥物資協會), a vice president of China Pharmaceutical Innovation and Research Development Association (中國醫藥創新促進會), the honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association (上海市生物醫藥行業協會), and a member of the 13th Shanghai Standing Committee of the Chinese People’s Political Consultative Conference. Mr. Chen was awarded “Asia’s Best CEO” by Corporate Governance Asia, etc.. Mr. Chen obtained a bachelor’s degree in genetics from Fudan University (復旦大學) in the PRC in July 1993 and a master’s degree of business administration from China Europe International Business School (中歐國際工商學院) in the PRC in September 2005. 

Ms. Xiaohui Guan (關曉暉), aged 52, has been a non-executive director of the Company since December 2018. Ms.Guan joined Fosun Pharma Group in May 2000, and successively served as a vice president, chief accountant and general manager of finance department, the senior vice president and chief financial officer, the executive president and chief financial officer of Fosun Pharma. Ms. Guan has been an executive director of Fosun Pharma since December 2021, and the vice chairman of the board of Fosun Pharma since January 2022. Ms. Guan currently serves as the vice president of Fosun International, a non-executive director of Gland Pharma and the chairman of the board of supervisors of Sinopharm. Ms. Guan served as a non-executive director of Sinopharm from March 2019 to March 2021. Prior to joining Fosun Pharma Group, Ms. Guan worked at Jiangxi Branch of Industrial and Commercial Bank of China. Ms. Guan obtained a bachelor’s degree of economics from Jiangxi University of Finance and Economics (江西財經大學) in the PRC in June 2000 and acquired a master’s degree of professional accountancy from Chinese University of Hong Kong in December 2007. Ms. Guan is qualified as Chinese Certified Public Accountant and a member of the Association of Chartered Certified Accountants. 

Mr. Deyong Wen (文德鏞), aged 51, has been a non-executive director of the Company since July 2022. Mr. Wen joined Fosun Pharma Group in May 2002 and successively served as vice president, senior vice president, co-president, president of Fosun Pharma and serves as the chief executive officer of Fosun Pharma since June 2022, and serves an executive director of Fosun Pharma since August 2022. Mr. Wen currently serves as a non-executive director of Sinopharm, a director of China National Medicines Corporation Ltd.* (國藥集團藥業股份有限公司) (Shanghai Stock Exchange stock code: 600511), and the chairman of the board of supervisors of China National Accord Medicines Corporation Ltd.* (國藥集團一致藥業股份有限公司) (Shenzhen Stock Exchange stock code: 000028). Mr. Wen served as a director of C.Q. Pharmaceutical Holdings Co., Ltd.* (重藥控股股份有限公司) (Shenzhen Stock Exchange stock code: 000950) and a director of Anhui Sunhere Pharmaceutical Excipients Co., Ltd.* (安徽山河藥用輔料股份有限公司) (Shenzhen Stock Exchange stock code: 300452). Prior to joining Fosun Pharma Group, Mr. Wen worked at Chongqing No. 6 Pharmaceutical Factory* (重慶製藥六廠) (the predecessor of Chongqing Yaoyou Pharmaceutical Co., Ltd.* (重慶藥友製藥有限責任公司)). Mr. Wen obtained a bachelor’s degree in pharmacy from West China University of Medical Sciences (華西醫科大學) (currently known as West China School of Medicine of Sichuan University (四川大學華西醫學中心)) in the PRC in June 1995, and obtained a master’s degree in business administration from Donghua University (東華大學) in the PRC in December 2007. 

Dr. Xingli Wang, aged 60, currently serves as the executive president of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (“Fosun Pharma”, together with its subsidiaries, “Fosun Pharma Group”). Dr. WANG has been the head of the global R&D center of Fosun Pharma and co-chief executive officer of Innovative Medicine Business Division since January 2023. Prior to joining Fosun Pharma Group, Dr. Wang served as a senior lecturer in cardiovascular medicine at The University of New South Wales, Australia, and as a cardiologist and adjunct professor at Baylor College of Medicine, USA, medical director of Schering-Plough Corporation, a company formerly listed on the NYSE (stock code: SGP) (merged into Merck & Co., Inc. in 2009). He also worked in Novartis AG (stock code: NVS), a company listed on the NYSE from October 2010 to May 2022, mainly serving as project director, global project clinical director, director of Novartis global drug R&D (China) and general manager of Biomedical Research Institute (China). Dr. WANG obtained a bachelor’s degree in medicine from Shandong Medical College (merged into Shandong University in 2000) and a doctorate degree in cardiovascular science from the UNSW. Dr. WANG also holds a license to practice medicine in Australia.

Mr. Tak Young So (蘇德揚), aged 52, has been an independent non-executive director of the Company since September 2019. Mr. So has been the founding and managing partner of FastLane Group since July 2012, an independent non-executive director of CARsgen Therapeutics Holdings Limited (Stock Exchange stock code: 02171) since June 2021 and an independent non-executive director of Goodbaby International Holdings Limited (Stock Exchange stock code: 01086) since May 2022. 

Mr. So has more than 20 years of experience in finance, accounting, investment and private equity businesses with global financial institutions and asset management companies. Mr. So served as a partner of Prospere Capital Limited from January 2018 to May 2022, the chief financial officer of PAG Capital from November 2011 to April 2012, the chief financial officer of Asia Pacific of asset management division for Deutsche Bank, Hong Kong from August 2007 to November 2011, the chief financial officer of Hamon Investment Group, an affiliate of Bank of New York Mellon from February 2005 to August 2007, the head of finance and operations of consumer banking in Hong Kong, head of asset and liability management of Greater China/Asia Pacific and chief financial officer of consumer, commercial and private bank in Hong Kong of ABN AMRO Bank N.V., Hong Kong from March 2002 to January 2005, the vice president of global capital market/Asia treasury and vice president of financial controls of Bank of America, Hong Kong from January 1998 to March 2002, group audit and project manager of strategic and performance improvement group in the Sydney office of Commonwealth Bank of Australia from January 1995 to January 1998, and an auditor with Ernst & Young, Hong Kong from February 1993 to December 1994. Mr. So obtained a bachelor’s degree of business in accounting and finance and a master’s degree of business administration in banking from the University of Technology in Sydney, Australia in April 1994 and September 1998, respectively. He has been a fellow member of the Australian Society of Certified Practising Accounting Australia (FCPA) since August 2011. 

Dr. Guoping Zhao (趙國屏), aged 74, has been an independent non-executive director of the Company since September 2019. Dr. Zhao is a molecular microbiologist. Currently, he has been the chairman of the Advisory Committee of Key Laboratory of Synthetic Biology of the Center for Excellence in Molecular Plant Science of the Chinese Academy of Sciences (CAS) (中國科學院分子植物科 學卓越創新中心合成生物學重點實驗室), the director of Department of Microbiology and Immunology at the School of Life Sciences of Fudan University (復旦大學生命科學學院微生物學與免疫學系) and the chief scientist of Biomedical Big Data Center at the Shanghai Institute of Nutrition and Health of CAS (中國科學院上海營養與健康研究所生物醫學大數據中心). Dr. Zhao was elected as a member of the Chinese Academy of Sciences (中國科學院院士) in 2005, a fellow of the World Academy of Sciences for the advancement of science in developing countries (發展中國家科學院院士) in 2011 and a member of the American Academy of Microbiology in February 2022. 

Dr. Ruilin Song (宋瑞霖), aged 60, has been an independent non-executive director of the Company since September 2019. Dr. Song has been a non-executive director of Luye Pharma Group Ltd.* (綠葉製藥集團有限公司) (Stock Exchange stock code: 02186) since March 2017, an independent director of Shenzhen Chipscreen Biosciences Co., Ltd.* (深圳微芯生物有限公司) (Star Market of the Shanghai Stock Exchange stock code: 688321) since August 2018, an independent non-executive director of Simcere Pharmaceutical Group Limited* (先聲藥業集團有限公司) (Stock Exchange stock code: 02096) since November 2019, an independent non-executive director of Jacobio Pharmaceuticals Group Co., Ltd.* (加科思藥業集團有限公司) (Stock Exchange stock code: 01167) since December 2020, and an independent non-executive director of Mediwelcome Healthcare Management & Technology Inc.* (麥迪衛康健康醫療管理科技股份有限公司) (Stock Exchange stock code: 02159) since December 2020. Dr. Song served as an independent director of Jiangxi Boya Bio-pharmaceutical Co., Ltd.* (江西博雅生物製藥股份有限公司) (Shenzhen Stock Exchange stock code: 300294) from March 2017 to March 2021, an independent director of Shanxi Zhendong Pharmaceutical Co., Ltd.* (山西振東製藥股份有限公司) (Shenzhen Stock Exchange stock code: 300158) from June 2015 to June 2021, and an independent director of Tibet Aim Pharm. Inc.* (西藏易明西雅醫藥科技股份有限公司) (Shenzhen Stock Exchange stock code: 002826) from August 2015 to August 2021. 

During the time he worked in the Legislative Affairs Office of the State Council of China, Dr. Song was mainly engaged in the legislative review and research of health and medicine for over 20 years. He participated in China’s health and drug legislation activities from 1987 to 2006, in charge of the drafting and review of laws and regulations of the current Drug Administration Law of the PRC, Law of the PRC on the Prevention and Treatment of Communicable Diseases, Law of the PRC on Medical Practitioners, Regulations on Medical Institutions, and Regulations for the Supervision and Administration of Medical Devices, etc. 

Since 2007, Dr. Song has been dedicated to the research of China’s pharmaceutical policies, especially the policies for pharmaceutical innovation. Under his leadership, Research Center for Medicinal Policy of Chinese Pharmaceutical Association and PhIRDA (中國醫藥創新促進會) had finalised dozens of research projects. Dr. Song has been the executive president of PhIRDA (formerly known as China Pharmaceutical Industry Research and Development Association (中國醫藥工業科研開發促進會) from November 2009 to September 2019, the president of PhIRDA from September 2019 to September 2020, and executive president of PhIRDA since September 2020. Dr. Song also served as specially-invited expert of Talent Pool Participating in and Discussing State Affairs of the CPPCC, consultant expert of Participating in and Discussing State Affairs of the Chinese Peasants and Workers Democratic Party, executive deputy director of National Drug Policy and Industrial Development Research Center of China Pharmaceutical University, visiting researcher of Shanghai Jiao Tong University, member of Advisory Committee for Traditional Chinese Medicine Strategic Decision of National Medical Products Administration, expert of the Price and Cost Investigation Center of the National Development and Reform Commission, vice chairman of China Alliance of Rare Diseases (CARD), honorary director of Chinese Pharmaceutical Association (CPA), honorary director of Chinese Pharmacist Association and a member of the Biotech Advisory Panel of the Stock Exchange among other important social positions. Dr. Song obtained a bachelor of laws degree from China University of Political Science and Law (中國政法大學) in June 1985, a master’s degree in business administration from China Europe International Business School (中歐國際工商學院) in the PRC in November 2004 and a doctoral degree in social and administrative pharmacy from China Pharmaceutical University (中國藥科大學) in December 2018.